Han E H, Kim H G, Im J H, et al. Up-regulation of CYP1A1 by rutaecarpine is dependent on aryl hydrocarbon receptor and calcium[J]. Toxicology, 2009, 266:38.
[5]
Don M J, Lewis D F V, Wang S Y, et al. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1[J]. Bioorg Med Chem Lett, 2003, 13:2535.
[6]
Chatterjee P, Franklin M R. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components [J]. Drug Metab Dispos, 2003, 31(11):1391.
[7]
Henderson G L, Harkey M R, Gershwin M E, et al. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity [J]. Life Sci, 1999, 65:209.
von Mohke L L, Weemhoff J L, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba [J]. J Pharm Pharmacol, 2004, 56(8):1039.
[10]
Chang T K, Chen J, Teng X W. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured Hepatocytes [J]. Drug Metab Dispos, 2006, 34(2):234.
Doehmer J, Weiss G, McGregor G P, et al. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities[J]. Toxicol In Vitro, 2011, 25(1):21.
Zhou S F, Koh H L, Gao Y H, et al. Herbal bioactivation: the good, the bad and the ugly[J]. Life Sci, 2004, 74:935.
[19]
Shimada T, Yamazaki H, Mimura, et at, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians[J]. J Pharmacol Exp Ther, 1994, 270:414.
[20]
Kolars J C, Lown K S, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium[J]. Pharmacogenetics, 1994, 4:247.
[21]
Tassaneeyakul W, Guo L Q, Fukuda K, et al. Inhibition selectivity of grape fruit juice components on human cytochromes P450 [J]. Arch Biochem Biophys, 2000, 378(2):356.
[22]
Kimura Y, Ito H, Ohnishi R, et al. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity [J]. Food Chem Toxicol, 2010, 48:429.
Wen Y H, Sahi J, Urda E, et al. Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes [J]. Drug Metab Dispos, 2002, 30(9):977.
[25]
Takeuchi H, Saoo K, Yokohira M, et al. Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice [J]. Cancer Res, 2003, 63(22):7581.
[26]
Yano J K, Hsu M H, Griffin K J, et al. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen[J]. Nat Struct Mol Biol, 2005, 12(9):822.
Chan H Y, Leung L K. A potential protective mechanism of soya isoflavones against 7,12-dimethylbenz anthracene tumour initiation[J]. Br J Nutr, 2003, 90(2):457.
[29]
Henderson M C, Miranda C L, Stevens J F, et al. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, humulus lupulus[J]. Xenobiotica, 2000, 30(3):235.
[30]
Schwarz D, Kisselev P, Roots I. CYP1A1 genotype-selective inhibition of benzo pyrene activation by quercetin[J]. Eur J Cancer, 2005, 41:151.
[31]
Doostdar H, Burke M D, Mayer R T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1 [J]. Toxicol, 2000, 144(1/3):31.
[32]
Walle T, Walle U K. Novel methoxylated flavone inhibitors of cytochrome P450 1B1 in SCC-9 human oral cancer cells [J]. J Pharm Pharmacol, 2007, 59(6):857.
[33]
Wen X, Walle U K, Walle T. 5,7-Dimethoxyflavone down regulates CYP1A1 expression and benzo pyrene-induced DNA binding in HepG2 cells[J]. Carcinogenesis, 2005, 26(4):803.
[34]
Ho P C, Saville D J, Wanwimolruk S. Inhibition of human CYP3A4 activity by grape fruit flavonoids, furanocoumarins and related compounds[J]. J Pharm Pharm Sci, 2001, 4(3):217.
[35]
Breinholt V M, Rasmussen S E, Brsen K, et al. In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s[J]. Pharmacol Toxicol, 2003, 93(1):14.
[36]
Backman J T, Menp J, Belle D J, et al. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation [J]. Clin Pharmacol Ther, 2000, 67(4):382.
[37]
Pouget C, Fagnere C, Basly J P, et al. Synthesis and aromatase inhibitory activity of flavanones [J]. Pharm Res, 2002, 19(3):286.
[38]
Ta N, Walle T. Aromatase inhibition by bioavailable methylated flavones [J]. J Steroid Biochem Mol Biol, 2007, 107(1/2):127.
Androutsopoulos V P, Papakyriakou A, Vourloumis D, et al. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes [J]. Pharmacol Ther, 2010, 126:9.
[42]
Simanek V, Walterova D, Vicar J, et al. Silymarin-an extract from the milk thistle (Silybum marianum)-is it a drug or nutritional supplement? [J]. Ceska Slov Farm, 2001, 50(2):66.
[43]
Zuber R, Modriansk M, Dvork Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities [J]. Phytother Res, 2002, 16(7):632.
[44]
Chang T K, Lee W B, Ko H H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogenactivating human cytochrome P450 1B1 [J]. Can J Physiol Pharmacol, 2000, 78:874.
[45]
Chun Y J, Ryu S Y, Jeong T C, et al. Mechanism based inhibition of human cytochrome P450 1A1 by rhapontigenin [J]. Drug Metab Dispos, 2001, 29:389.
Xia C H, Sun J G, Wang G J, et al. Herb-drug interactions: in vivo and in vitro effect of shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats[J]. Planta Med, 2010, 76(3):245.
